MEDINCELL S.A.
The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group
Ivermectin administered for 28 days demonstrated acceptable safety and tolerability without any unexpected safety signals
The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell's proprietary technology, BEPO®
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medincell SA published this content on 05 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2023 19:57:07 UTC.
